PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022

Summary

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. These factors will be particularly true in the emerging markets where uptake of branded drugs will increase due to rapid economic growth.

Highlights

Key Questions Answered

- The Obesity market is marked by the presence of several key unmet needs. What are these main unmet needs? Will the drugs under development fulfil these unmet needs? How do physicians and payers perceive these pipeline and currently marketed drugs?
- Only one older generation drug with modest efficacy had been available until the recent arrival of two new therapies that could potentially change the prescribing landscape. Will these drugs make a significant impact on the Obesity market? Which drugs are used off-label for the treatment of obesity?
- The diagnosed prevalence of Obesity in the world skyrocketed in the past 10 years and will continue increasing at a fast pace. How will epidemiological changes impact the growth of the future market? How does the burden of comorbidities associated with overweight and obesity impact the treatment algorithm?

Key Findings

- The main driver of growth of the Obesity market will be the growing population of overweight and obese individuals needing pharmacological intervention and the subsequent rise in the obesity-related comorbidities to put obesity at the forefront of the medical community as a veritable disease with life-threatening implications.
- The second largest driver will be the physicians’ efforts to delay disease progression through the use of combination therapies and novel branded drugs with greater efficacy and better safety profiles.
- To ensure patients gain access to novel, life-saving therapies, companies need to establish an agreement with third party payers to beholden them to a larger share of the responsibility for drug therapy reimbursement.
- To date, no drug has achieved blockbuster status. This unmet need presents a large opportunity for drug developers to capture an unoccupied market space.

Scope

- Overview of Obesity, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized Obesity therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Obesity therapeutics market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global Obesity therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global Obesity therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global Obesity therapeutics market from 2012-2022.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

1 Table of Contents
1 Table of Contents 8


2 Introduction 24
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 29
3.2 Symptoms 31
4 Epidemiology 32
4.1 Disease Overview 32
4.2 Risk Factors and Comorbidities 33
4.3 Global Trends 39
4.4 Forecast Methodology 55
4.5 Epidemiology Forecast of Overweight (2012-2022) 88
4.6 Epidemiology Forecast of Obesity (2012-2022) 95
4.7 Epidemiology Forecast of Obesity Class I (2012-2022) 102
4.8 Epidemiology Forecast of Obesity Class II (2012-2022) 109
4.9 Epidemiology Forecast of Obesity Class III (2012-2022) 118
4.10 Epidemiology Forecast of Comorbidities among Adults with Overweight/Obesity (2012 and 2022) 126
4.11 Discussion 133
5 Disease Management 136
5.1 Treatment Overview 136
5.2 US 142
5.3 France 147
5.4 Germany 151
5.5 Italy 158
5.6 Spain 163
5.7 UK 165
5.8 Japan 168
5.9 Brazil 171
5.10 Canada 177
6 Competitive Assessment 180
6.1 Overview 180
6.2 Strategic Competitor Assessment 184
6.3 Product Profiles: Drugs 186
6.4 Product Profiles: Medical Devices - Artifical Fulness Devices 219
6.5 Product Profiles: Medical Devices - Endoscopic Surgical Devices 240
6.6 Product Profiles: Medical Devices - Gastric Electrical Stimulation 249
6.7 Product Profiles: Medical Devices - Malabsorption Devices 257
6.8 Product Profiles: Medical Devices - Neuronal Blocking Technology 260
6.9 Product Profiles: Medical Devices - Restrictive Devices 262
7 Opportunity and Unmet Need 286
7.1 Overview 286
7.2 A Drug with Greater Than 10% Average Weight Loss 288
7.3 A Drug with Increased Safety and Tolerability 290
7.4 Reimbursement by Private and Public Payers 292
7.5 Increased Physician Education 295
7.6 Increased Drug-Treatment Rate 297
7.7 Improved Guidelines 299
7.8 Improved Approach to Diagnosis 301
8 Pipeline Assessment 302
8.1 Overview 302
8.2 Clinical Trial Mapping 306
8.3 Clinical Trials by Phase and Trial Status 307
8.4 Promising Drugs in Clinical Development 308
8.5 Artificial Fullness Devices 338
8.6 Promising Deep-Brain Stimulation Devices in Development 342
8.7 Promising Endoscopic Surgical Devices 345
8.8 Promising Malabsorption Devices in Development 349
8.9 Promising Restrictive Devices in Development 351
9 Current and Future Players 358
9.1 Overview 358
9.2 Trends in Corporate Strategy 363
9.3 Company Profiles: Pharmaceutical and Biotech Companies 364
9.4 Company Profiles: Device Companies 383
10 Market Outlook 419
10.1 Global Markets 421
10.2 United States 431
10.3 France 440
10.4 Germany 446
10.5 Italy 453
10.6 Spain 460
10.7 United Kingdom 466
10.8 Japan 473
10.9 Brazil 479
10.10 Canada 486
11 Appendix 492
11.1 Bibliography 492
11.2 Abbreviations 515
11.3 Research Methodology 521
11.4 Forecasting Methodology 522
11.5 Physicians, Specialists, and Payers Included in This Study 530
11.6 About the Authors 532
11.7 About GlobalData 535
11.8 Disclaimer 535

1.1 List of Tables
Table 1: Target Pathways in the Treatment of Obesity 36
Table 2: Symptoms of Obesity 37
Table 3: The WHO Classification System of Adult Overweight and Obesity According to BMI 38
Table 4: Risk Factors and Comorbidities of Obesity 39
Table 5: 9MM, Age-Adjusted and Crude Prevalence (%) of Obesity, by Sex, Ages ? 20 Years, 2008 46
Table 6: JASSO and WHO Classifications of Obesity 55
Table 7: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Overweight 62
Table 8: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity 63
Table 9: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity Class I, Class II, and Class III 65
Table 10: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Comorbidities in Overweight/Obese 67
Table 11: 9MM, Prevalent Cases of Overweight, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 95
Table 12: 9MM, Prevalent Cases of Overweight, by Age, Both Sexes, N (Millions), Row (%), 2012 97
Table 13: 9MM, Prevalent Cases of Overweight, Ages ? 18 Years, by Sex, N (Millions), Row (%), 2012 98
Table 14: 9MM, Prevalent Cases of Obesity, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 102
Table 15: 9MM, Prevalent Cases of Obesity, by Age, Both Sexes, N (Millions), Row (%), 2012 103
Table 16: 9MM, Prevalent Cases of Obesity, Ages ? 18 Years, by Sex, N (Millions), Row (%), 2012 105
Table 17: 9MM, Prevalent Cases of Obesity Class I, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 109
Table 18: 9MM, Prevalent Cases of Obesity Class I, by Age, Both Sexes, N (Millions), Row (%), 2012 111
Table 19: 9MM, Prevalent Cases of Obesity Class I, Ages ? 18 Years, by Sex, N (Millions), Row (%), 2012 112
Table 20: 9MM, Prevalent Cases of Obesity Class II, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 116
Table 21: 9MM, Prevalent Cases of Obesity Class II, by Age, Both Sexes, N (Millions), Row (%), 2012 119
Table 22: 9MM, Prevalent Cases of Obesity Class II, Ages ? 18 Years, by Sex, N (Millions), Row (%), 2012 121
Table 23: 9MM, Prevalent Cases of Obesity Class III, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 125
Table 24: 9MM, Prevalent Cases of Obesity Class III, by Age, Both Sexes, N (Millions), Row (%), 2012 128
Table 25: 9MM, Prevalent Cases of Obesity Class III, Ages ? 18 Years, by Sex, N (Millions), Row (%), 2012 129
Table 26: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022 132
Table 27: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022 135
Table 28: 4MM, Prevalent Cases of Dyslipidemia* among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022 137
Table 29: Treatment Guidelines for Obesity 145
Table 30: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 146
Table 31: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 147
Table 32: Brazilian Classification of Overweight and Obesity 177
Table 33: Bariatric Treatment Attributes 189
Table 34: Leading Drug Treatments for Obesity, 2013 190
Table 35: Marketed Obesity Treatment Devices by Type 191
Table 36: Product Profile - Phentermine 193
Table 37: Phentermine SWOT Analysis, 2013 196
Table 38: Global Sales Forecasts ($m) for Phentermine, 2012-2022 197
Table 39: Global Sales Forecasts ($m) for Phentermine + Topiramate, 2012-2022 197
Table 40: Product Profile - Xenical 199
Table 41: Xenical SWOT Analysis, 2013 201
Table 42: Global Sales Forecasts ($m) for Xenical, 2012-2022 202
Table 43: Product Profile - Qsymia 204
Table 44: Qsymia SWOT Analysis, 2013 208
Table 45: Global Sales Forecasts ($m) for Qsymia, 2012-2022 209
Table 46: Product Profile - Belviq 212
Table 47: Belviq SWOT Analysis, 2013 214
Table 48: Global Sales Forecasts ($m) for Belviq, 2012-2022 215
Table 49: Product Profile - Topiramate 217
Table 50: Topiramate SWOT Analysis, 2013 220
Table 51: Product Profile - Oblean 222
Table 52: ObleanSWOT Analysis, 2013 223
Table 53: Global Sales Forecasts ($m) for Oblean, 2012-2022 224
Table 54: Product Profile - End Ball 227
Table 55: End Ball SWOT Analysis 228
Table 56: Product Profile - Obalon 229
Table 57: Obalon SWOT Analysis 231
Table 58: Product Profile - Orbera 232
Table 59: Orbera SWOT Analysis 234
Table 60: Product Profile - Heliosphere 235
Table 61: Heliosphere SWOT Analysis 237
Table 62: Product Profile - ReShape Duo 238
Table 63: ReShape Duo SWOT Analysis 239
Table 64: Product Profile - SatiSphere 240
Table 65: SatiSphere SWOT Analysis 241
Table 66: Product Profile - Spatz 242
Table 67: Spatz SWOT Analysis 245
Table 68: Product Profile - Intraluminal Circular Stapler 247
Table 69: Intraluminal Circular Stapler SWOT Analysis 248
Table 70: Product Profile - OverStitch 249
Table 71: OverStitch SWOT Analysis 251
Table 72: Product Profile - StomaphyX 252
Table 73: StomaphyX SWOT Analysis 254
Table 74: Product Profile - Abiliti 257
Table 75: Abiliti SWOT Analysis 259
Table 76: Product Profile - DIAMOND Tantalus 260
Table 77: DIAMOND Tantalus SWOT Analysis 262
Table 78: Product Profile - EndoBarrier 263
Table 79: EndoBarrier SWOT Analysis 265
Table 80: Product Profile - Vbloc Maestro System 266
Table 81: Vbloc Maestro System SWOT Analysis 267
Table 82: Product Profile - AMI Band 270
Table 83: AMI Band SWOT Analysis 272
Table 84: Product Profile - Bioring 273
Table 85: Bioring SWOT Analysis 275
Table 86: Product Profile - Heliogast 277
Table 87: Heliogast SWOT Analysis 278
Table 88: Product Profile - Lap-Band 279
Table 89: Lap-Band SWOT Analysis 282
Table 90: Product Profile - Midband 283
Table 91: SWOT Analysis 285
Table 92: Product Profile - MiniMizer Extra 286
Table 93: SWOT Analysis 288
Table 94: Product Profile - Swedish/Realize Band 289
Table 95: Swedish/Realize Band SWOT Analysis 291
Table 96: Unmet Need and Opportunity in Obesity 293
Table 97: Endpoint Analysis of Clinical Trials Conducted in Obesity, 2013 310
Table 98: Obesity- Clinical Trials by Phase and Trial Status, 2012 313
Table 99: Obesity - Phase II-III Pipeline, 2013 314
Table 100: Comparison of Therapeutic Classes in Development for Obesity, 2013 316
Table 101: Obesity Treatment Pipeline Devices by Type 316
Table 102: Product Profile - Contrave 318
Table 103: Contrave SWOT Analysis, 2013 321
Table 104: Global Sales Forecasts ($m) for Contrave, 2012-2022 322
Table 105: Product Profile - Victoza 324
Table 106: Victoza SWOT Analysis, 2013 328
Table 107: Global Sales Forecasts ($m) for Victoza, 2012-2022 329
Table 108: Product Profile - Velneperit 330
Table 109: Velneperit SWOT Analysis, 2013 333
Table 110: Global Sales Forecasts ($m) for Velneperit, 2012-2022 334
Table 111: Product Profile - Empatic 336
Table 112: Empatic SWOT Analysis, 2013 339
Table 113: Global Sales Forecasts ($m) for Empatic, 2012-2022 340
Table 114: Obesity - Promising Early-Stage Approaches, 2013 341
Table 115: Product Profile - Full Sense Device 344
Table 116: Full Sense Device SWOT Analysis 345
Table 117: Product Profile - TransPyloric Shuttle 346
Table 118: TransPyloric Shuttle SWOT Analysis 347
Table 119: Product Profile - Deep Brain Stimulation Device 349
Table 120: Deep Brain Stimulation Device SWOT Analysis 350
Table 121: Product Profile - ACE Stapler 351
Table 122: ACE Stapler SWOT Analysis 352
Table 123: Product Profile - RS2 Restore 353
Table 124: RS2 Restore SWOT Analysis 354
Table 125: Product Profile - ValenTx 356
Table 126: ValenTx SWOT Analysis 356
Table 127: Product Profile - AMI B-Band 357
Table 128: AMI B-Band SWOT Analysis 358
Table 129: Product Profile - AMI Basket 359
Table 130: AMI Basket SWOT Analysis 360
Table 131: Product Profile - TERIS 361
Table 132: TERIS SWOT Analysis 363
Table 133: Key Companies in the Obesity Market, 2013 368
Table 134: Orexigen’s Disease/Therapy Portfolio Assessment, 2013 372
Table 135: Orexigen Therapeutics SWOT Analysis, 2013 373
Table 136: Novo Nordisk’s Disease/Therapy Portfolio Assessment, 2013 374
Table 137: Novo Nordisk SWOT Analysis, 2013 375
Table 138: Takeda’s Disease / Therapy Portfolio Assessment, 2013 376
Table 139: Takeda SWOT Analysis, 2013 377
Table 140: Shionogi’s Disease/Therapy Portfolio Assessment, 2013 379
Table 141: Shionogi SWOT Analysis, 2013 379
Table 142: Roche Holding’s Disease/Therapy Portfolio Assessment, 2013 381
Table 143: Roche Holdings SWOT Analysis, 2013 381
Table 144: Vivus’ Disease/Therapy Portfolio Assessment, 2013 385
Table 145: Vivus SWOT Analysis, 2013 385
Table 146: Arena Pharmaceuticals’ Disease/Therapy Portfolio Assessment, 2013 388
Table 147: Arena and Eisai SWOT Analysis, 2013 388
Table 148: Company Profile - Allergan 390
Table 149: Allergan SWOT Analysis 391
Table 150: Company Profile - Apollo Endosurgery 392
Table 151: Apollo Endosurgery SWOT Analysis 393
Table 152: Company Profile - Aspire Bariatrics 394
Table 153: Aspire Bariatrics SWOT Analysis 394
Table 154: Company Profile - AMI 395
Table 155: AMI SWOT Analysis 396
Table 156: Company Profile - Bariatric Solutions 396
Table 157: Bariatric Solutions SWOT Analysis 397
Table 158: Company Profile - Baronova 397
Table 159: Baronova SWOT Analysis 398
Table 160: Company Profile - BaroSense 399
Table 161: BaroSense SWOT Analysis 400
Table 162: Company Profile - BFKW 401
Table 163: BFKW SWOT Analysis 401
Table 164: Company Profile - Cousin Biotech 402
Table 165: Cousin Biotech SWOT Analysis 403
Table 166: Company Profile - CR Bard 404
Table 167: CR Bard SWOT Analysis 404
Table 168: Company Profile - Endalis Laboratory 405
Table 169: Endalis Laboratory SWOT Analysis 405
Table 170: Company Profile - EndoGastric Solutions 406
Table 171: EndoGastric Solutions SWOT Analysis 407
Table 172: Company Profile - EndoSphere 408
Table 173: EndoSphere SWOT Analysis 408
Table 174: Company Profile - EnteroMedics 409
Table 175: EnteroMedics SWOT Analysis 410
Table 176: Company Profile - Ethicon Endo-Surgery 411
Table 177: Ethicon Endo-Surgery SWOT Analysis 412
Table 178: Company Profile - GI Dynamics 413
Table 179: GI Dynamics SWOT Analysis 413
Table 180: Company Profile - Helioscopie 414
Table 181: Helioscopie SWOT Analysis 414
Table 182: Company Profile - IntraPace 415
Table 183: IntraPace SWOT Analysis 416
Table 184: Company Profile - Medical Innovation Development 417
Table 185: Medical Innovation Development SWOT Analysis 418
Table 186: Company Profile - MetaCure 419
Table 187: MetaCure SWOT Analysis 419
Table 188: Company Profile - Obalon Therapeutics 420
Table 189: Obalon Therapeutics SWOT Analysis 421
Table 190: Company Profile - ReShape Medical 422
Table 191: ReShape Medical SWOT Analysis 422
Table 192: Company Profile - Spatz Medical 423
Table 193: Spatz Medical SWOT Analysis 423
Table 194: Company Profile - ValenTx 424
Table 195: ValenTx SWOT Analysis 424
Table 196: Global Sales Forecasts ($m) for Obesity, 2012-2022 427
Table 197: Global Obesity Market - Drivers and Barriers, 2012-2012 429
Table 198: Sales Forecasts ($) for Obesity in the United States, 2012-2022 439
Table 199: Key Events Impacting Sales for Obesity in the United States, 2012-2022 441
Table 200: Obesity Market in the United States - Drivers and Barriers, 2012-2022 442
Table 201: Sales Forecasts ($) for Obesity in France, 2012-2022 447
Table 202: Key Events Impacting Sales for Obesity in France, 2012-2022 449
Table 203: Obesity Market in France - Drivers and Barriers, 2012-2022 450
Table 204: Sales Forecasts ($) for Obesity in Germany, 2012-2022 454
Table 205: Key Events Impacting Sales for Obesity in Germany, 2012-2022 456
Table 206: Obesity Market in Germany - Drivers and Barriers, 2012-2022 457
Table 207: Sales Forecasts ($) for Obesity in Italy, 2012-2022 461
Table 208: Key Events Impacting Sales for Obesity in Italy, 2012-2022 463
Table 209: Obesity Market in Italy - Drivers and Barriers, 2012-2022 464
Table 210: Sales Forecasts ($) for Obesity in Spain, 2012-2022 467
Table 211: Key Events Impacting Sales for Obesity in Spain, 2012-2022 469
Table 212: Obesity Market in Spain - Drivers and Barriers, 2012-2022 470
Table 213: Sales Forecasts ($) for Obesity in United Kingdom, 2012-2022 473
Table 214: Key Events Impacting Sales for Obesity in the United Kingdom, 2012-2022 475
Table 215: Obesity Market in the United Kingdom - Drivers and Barriers, 2012-2022 476
Table 216: Sales Forecasts ($) for Obesity in Japan, 2012-2022 480
Table 217: Events Impacting Sales for Obesity in Japan, 2012-2022 482
Table 218: Obesity Market in Japan - Drivers and Barriers, 2012-2022 483
Table 219: Sales Forecasts ($) for Obesity in Brazil, 2012-2022 487
Table 220: Key Events Impacting Sales for Obesity in Brazil, 2012-2022 489
Table 221: Obesity Market in Brazil - Drivers and Barriers, 2012-2022 490
Table 222: Sales Forecasts ($) for Obesity in Canada, 2012-2022 493
Table 223: Events Impacting Sales for Obesity in Canada, 2012-2022 495
Table 224: Obesity Market in Canada - Drivers and Barriers, 2012-2022 496
Table 225: Key Launch Dates 529
Table 226: Key Patent Expiries 529

1.2 List of Figures
Figure 1: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20-74 Years, Men, 1960-2010 47
Figure 2: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20-74 Years, Women, 1960-2010 48
Figure 3: France, Overweight and Obesity Prevalence (%), Ages ? 15 Years, Men, 1997-2006 50
Figure 4: France, Overweight and Obesity Prevalence (%), Ages ? 15 Years, Women, 1997-2006 50
Figure 5: Italy, Overweight and Obesity Prevalence (%), Ages ? 18, Men, 1983-2010 52
Figure 6: Italy, Overweight and Obesity Prevalence (%), Ages ? 18, Men, 1983-2010 52
Figure 7: UK, Overweight and Obesity Prevalence (%), Ages ? 16 Years, Men, 1993-2011 54
Figure 8: UK, Overweight and Obesity Prevalence (%), Ages ? 16 Years, Women, 1993-2011 54
Figure 9: Japan, Obesity Prevalence (%), Ages ? 20 Years, by Sex, 1976-2006 56
Figure 10: Brazil, Overweight and Obesity Prevalence (%), Ages ? 20 Years, Men, 1975-2003 57
Figure 11: Brazil, Overweight and Obesity Prevalence (%), Ages ? 20 Years, Women, 1975-2003 58
Figure 12: Canada, Obesity Prevalence (%), Ages ? 18 Years, Both Sexes, 1978-2008 60
Figure 13: 9MM, Prevalent Cases of Overweight, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 95
Figure 14: 9MM, Prevalent Cases of Overweight, by Age, Both Sexes, N (Millions), 2012 97
Figure 15: 9MM, Prevalent Cases of Overweight, Ages ? 18 Years, by Sex, N (Millions), 2012 99
Figure 16: 9MM, Overweight Age-Standardized Prevalence (%), Ages ? 18 Years, by Sex, 2012 100
Figure 17: 9MM, Prevalent Cases of Obesity, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 102
Figure 18: 9MM, Prevalent Cases of Obesity, by Age, Both Sexes, N (Millions), 2012 104
Figure 19: 9MM, Prevalent Cases of Obesity, Ages ? 18 Years, by Sex, N (Millions), 2012 106
Figure 20: 9MM, Obesity Age-Standardized Prevalence (%), Ages ? 18 Years, by Sex, 2012 107
Figure 21: 9MM*, Prevalent Cases of Obesity Class I, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 109
Figure 22: 9MM*, Prevalent Cases of Obesity Class I, by Age, Both Sexes, N (Millions), 2012 111
Figure 23: 9MM*, Prevalent Cases of Obesity Class I, Ages ? 18 Years, by Sex, N (Millions), 2012 113
Figure 24: 9MM*, Obesity Class I Age-Standardized Prevalence (%), Ages ? 18 Years, by Sex, 2012 114
Figure 25: 9MM*, Prevalent Cases of Obesity Class II, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 117
Figure 26: 9MM*, Prevalent Cases of Obesity Class II, by Age, Both Sexes, N (Millions), 2012 119
Figure 27: 9MM*, Prevalent Cases of Obesity Class II, Ages ? 18 Years, by Sex, N (Millions), 2012 122
Figure 28: 9MM*, Age-Standardized Prevalence (%) of Obesity Class II, Ages ? 18 Years, by Sex, 2012 123
Figure 29: 9MM*, Prevalent Cases of Obesity Class III, Ages ? 18 Years, Both Sexes, N (Millions), 2012-2022 126
Figure 30: 9MM*, Prevalent Cases of Obesity Class III, by Age, Both Sexes, N (Millions), 2012 128
Figure 31: 9MM*, Prevalent Cases of Obesity Class III, Ages ? 18 Years, by Sex, N (Millions), 2012 130
Figure 32: 9MM*, Obesity Class III Age-Standardized Prevalence (%), Ages ? 18 Years, by Sex, 2012 131
Figure 33: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 133
Figure 34: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 136
Figure 35: 4MM*, Prevalent Cases of Dyslipidemia** among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 138
Figure 36: Treatment Algorithm for Obesity 144
Figure 37: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in the United States, 2012-2022 148
Figure 38: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in France, 2012-2022 154
Figure 39: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Germany, 2012-2022 158
Figure 40: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Italy, 2012-2022 165
Figure 41: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Spain, 2012-2022 169
Figure 42: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in the United Kingdom, 2012-2022 172
Figure 43: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Japan, 2012-2022 174
Figure 44: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Brazil, 2012-2022 178
Figure 45: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Canada, 2012-2022 183
Figure 46: Obesity Therapeutics - Clinical Trials by Country, 2012 312
Figure 47: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012-2022 315
Figure 48: Company Portfolio Gap Analysis in Obesity, 2012-2022 368
Figure 49: Global Sales for Obesity by Region, 2012-2022 428
Figure 50: Sales for Obesity in the United States by Drug Class, 2012-2022 440
Figure 51: Sales for Obesity in France by Drug Class, 2012-2022 448
Figure 52: Sales for Obesity in Germany by Drug Class, 2012-2022 455
Figure 53: Sales for Obesity in Italy by Drug Class, 2012-2022 462
Figure 54: Sales for Obesity in Spain by Drug Class, 2012-2022 468
Figure 55: Sales for Obesity in the United Kingdom by Drug Class, 2012-2022 474
Figure 56: Sales for Obesity in Japan by Drug Class, 2012-2022 481
Figure 57: Sales for Obesity in Brazil by Drug Class, 2012-2022 488
Figure 58: Sales for Obesity in Canada by Drug Class, 2012-2022 494

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

According to WHO approximately 17.3 million people die annually due to CVD and the condition is responsible for 30 percent of the global deaths. Also, 80 percent of CVD deaths take place in low and middle ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.